MedPath

WHO Issues New Guidance for Clinical Trials to Enhance Global Research Standards

• The World Health Organization (WHO) has released new global guidance for clinical trials, applicable to all trials and observational studies, marking a significant milestone in standardizing research practices. • The guidance emphasizes embedding research within health systems, fostering researcher networks, and ensuring inclusivity of diverse populations, with a focus on patient and community engagement. • Key objectives include streamlining clinical trial approval processes and adopting a risk-based approach to design, data collection, oversight, and inspection, to improve efficiency and patient-centered research. • WHO is hosting a global event to present the guidance, aiming to catalyze discussions among stakeholders and advance a Global Action Plan on Clinical Trial Ecosystem Strengthening.

The World Health Organization (WHO) has launched new clinical trials guidance in September 2024, representing a major advancement in global research standards. This comprehensive guidance is designed to apply to all clinical trials, irrespective of whether they involve investigational products, and extends its relevance to observational studies.

Key Focus Areas

The new WHO guidance emphasizes several critical areas to enhance the quality and impact of clinical research:
  • Embedding Research into Health Systems: Integrating research activities directly into healthcare systems to ensure relevance and sustainability.
  • Developing Sustained Networks: Fostering continuous networks of clinical researchers to promote collaboration and knowledge sharing.
  • Inclusivity of Diverse Population Groups: Ensuring that clinical trials include diverse populations to improve the generalizability of findings.
  • Patient and Community Engagement: Highlighting the importance of interaction between patient/community groups and researchers throughout the trial lifecycle.
  • Streamlining Approval Processes: Simplifying the often complex and uncoordinated clinical trial approval processes involving multiple bodies.
  • Risk-Based Approach: Implementing a proportionate, risk-based approach to trial design, data collection, oversight, and inspection.

Objectives and Global Event

WHO, in collaboration with The Global Health Network, is hosting a global event to present the key aspects of this new guidance. The event aims to:
  • Outline how stakeholders can use the guidance to advance patient-centered clinical research.
  • Discuss how implementation could lead to more enabling and efficient clinical research ecosystems.
  • Raise awareness of a forthcoming Global Action Plan on Clinical Trial Ecosystem Strengthening.
  • Catalyze discussions on what stakeholder groups can do to take forward actions aligned with their strategies.
Dr. Jeremy Farrar, WHO Chief Scientist, and Dr. Vasee Moorthy, WHO Senior Advisor, Research for Health, will be presenting at the event, providing insights into how WHO can support clinical research and the practical applications of the new guidance.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Reference News

[1]
WHO launches new clinical trials guidance – What do I need to know?
who.int · Nov 5, 2024

The WHO guidance for best practices in clinical trials, published in Sept 2024, focuses on integrating research into hea...

© Copyright 2025. All Rights Reserved by MedPath